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Background: Recently, it has been found that Fructus Schisandra Chinensis (FSC), a Chinese herbal medicine, and its
related compounds have a profound impact on lipid metabolism process. FSC can be divided into two parts, i.e., seed
and pulp. The current study aimed to examine the effect of aqueous extracts of FSC pulp (AqFSC-P) on serum/hepatic
lipid and glucose levels in mice fed with a normal diet (ND) or a high cholesterol/bile salt diet (HCBD).
Methods: The AqFSC-P used in the present study was fractionated into supernatant (SAqFSC-P) and precipitate
(PAqFSC-P) separated by centrifugation. Male ICR mice were fed with ND or HCBD, without or with supplementation
of 1%, 3%, or 9% (w/w) SAqFSC-P or PAqFSC-P for 10 days. Biomarkers were determined according to the
manufacturer’s instruction.
Results: Supplementation with SAqFSC-P or PAqFSC-P significantly reduced serum and hepatic triglyceride levels
(approximately 40%) in ND- and/or HCBD-fed mice. The supplementation with SAqFSC-P or PAqFSC-P reduced
hepatic total cholesterol levels (by 27 − 46%) in HCBD-fed mice. Supplementation with SAqFSC-P or PAqFSC-P
markedly lowered hepatic glucose levels (by 13 − 30%) in ND- and HCBD-fed mice. SAqFSC-P decreased serum
alanine aminotransferase (ALT) activity, but PAqFSC-P increased hepatic protein contents in ND-fed mice. Bicylol,
as a positive control, reduced ALT activity. In addition, mice supplemented with FSC-P or bicylol showed a smaller
body weight gain and adipose tissue mass as compared to the respective un-supplemented ND- or HCBD-fed mice.
Conclusion: The results indicate that SAqFSC-P and PAqFSC-P produce hepatic lipid- and glucose-lowering as well as
serum TG-lowering effects in hypercholesterolemic mice. FSC pulp may provide a safe alternative for the management
of fatty liver and/or lipid disorders in humans.
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A growing body of evidence has shown that hyperlipid-
emia, regardless of cause, is an important factor involved
in the development of a wide range of human diseases,
including coronary heart disease (CHD) [1,2], nonalcoholic
fatty liver disease (NAFLD) [3] and metabolic syndrome* Correspondence: siyuanpan@163.com; yuzhiling@hotmail.com
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unless otherwise stated.[4]. Therefore, the searching for therapeutic intervention
aimed at lowering lipid levels in blood and the liver has
been an area of intensive research. While lipid-lowering
drugs can be used to lower the elevated levels of lipids in
patients with dyslipidemia [5], there is still no effective
drug for the treatment of NAFLD, which is manifested as
deposition of fat in the liver in patients without an exces-
sive consumption of alcohol. The commonly prescribed
lipid-lowering drugs can cause many potential adverse/side
effects, such as myopathies, renal impairment, hepatic
injury, and or pancreatitis [6,7]. Therefore, it is of clinical. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain











































Figure 1 Effects of dietary supplementation with SAqFSC-P,
PAqFSC-P, or bicyclol on serum TG and TC levels in normal and
hypercholesterolemic mice. Mice were fed with normal diet (ND)
or high cholesterol/bile salt (1%/0.3%, w/w) diet (HCBD) without and
with the supplementation with supernatant/precipitate of aqueous
extract of pulp from Fructus Schisandrae Chinesis [namely, SAqFSC-P/
PAqFSC-P (1%, 3%, or 9%, w/w)] or bicyclol (BL, 0.025%, w/w) for 10 days.
The concentrations of SAqFSC-P/PAqFSC-P were estimated on the basis
of crude herbal material. Serum triglyceride (TG) and total cholesterol (TC)
levels (as indicated in Figure A and B, respectively) were measured. Value
given are the means ± S.E.M., with n = 10. *P< 0.05, **P< 0.01 vs. control
ND; †P< 0.05, ††P< 0.01 vs. control HCBD, using a one-way ANOVA
followed by Dunnett’s multiple comparisons test or post-hoc analysis.
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ingredients such as coenzyme Q10 [8], phytosterols [9],
unsaturated fatty acids [10,11], probiotics [12], as well as
herbs [13,14].
Fructus Schisandra Chinensis (FSC, Wu-wei-zi in
Chinese), a traditional Chinese tonic herb, has been
used for thousands of years in China. In generally, FSC
can be divided into two parts — seed and pulp. Previous
studies have shown that FSC extract (both seed and pulp)
[15,16] or its active ingredient schisandrin B [17] and
other related compounds bicyclol [18] and bifendate [19]
can reduce hepatic triglyceride (TG) and total cholesterol
(TC) levels in mice with hypercholesterolemia induced by
high-fat diet containing cholesterol/bile salt. In this study,
we endeavored to investigate whether the two fractions
of the aqueous extract of FSC pulp (AqFSC-P), namely,
supernatant (SAqFSC-P) and precipitate (PAqFSC-P),
can decrease serum and hepatic lipid/glucose (GLU)
levels in normal and hypercholesterolemic mice. Serum or
hepatic lipids including TG, TC, low-density lipoprotein
(LDL), high-density lipoprotein (HDL), as well as HDL/
LDL, LDL/HDL, and non-HDL (N-HDL) were measured.
Bicyclol, a synthetic derivative of dibenzocyclooctadiene
lignans from the FSC, was used as positive control for
comparison. The objective of this study is to establish the
pharmacological basis for the potential use of FSC-P for
the treatment of the patients with hypertriglyceridemia,
fatty liver disease, and obesity. As the residue from the
manufacture process of FSC is often treated as waste, the
effects of supplementation with the precipitate of AqFSC-




Supplementation with SAqFSC-P and PAqFSC-P did not
affect serum TG and TC levels in mice fed with ND,
except for PAqFSC-P at a dose of 1% which showed a
significant decrease in serum TG level (Figure 1). While
HCBD feeding slightly decreased serum TG level, both
SAqFSC-P and PAqFSC-P supplementations further
decreased serum TG level (by 23 − 30%) in HCBD-fed
(i.e., hypercholesterolemic) mice (Figure 1A). HCBD
feeding markedly increased serum TC level by 53% in
mice (Figure 1B), but PAqFSC-P supplementations did
not affect serum TC levels in HCBD-fed mice. SAqFSC-P
(3%) decreased serum TC levels in hypercholesterolemic
mice. Bicyclol supplementation did not affect serum TG
and TC levels in both ND- and HCBD-fed mice. In
addition, although HCBD intake did not affect the serum
HDL levels, it increased serum LDL level, LDL/HDL ratio,
and N-HDL level by 440%, 500%, and 375%, respectively,
and decreased the HDL/LDL ratio by 83%. FSC-P treat-
ment did not affect serum HDL and LDL level in ND-fedmice. However, supplementation with PAqFSC-P (1% or
3%) attenuated N-HDL levels by 15 and 22%, respectively,
in HCBD-fed mice, when compared the un-supplemented
HCBD-fed mice (Table 1).
Hepatic lipid levels
Mice fed ND supplemented with 1% or 9% SAqFSC-P
for 10 days showed a significant decrease in hepatic TG
content by 9 and 22%, respectively (Figure 2A). Supple-
mentation with SAqFSC-P or PAqFSC-P at doses of
1% and 9% increased hepatic TC contents (by 6 − 18%)
Table 1 Effects of dietary supplementation with SAqFSC-P, PAqFSC-P, or bicyclol on serum lipoprotein profiles in
normal and hypercholesterolemic mice
Groups Drug concentration
(%, w/w)
HDL (mmol/L) LDL (mmol/L) HDL/LDL (mmol/L) LDL/HDL (mmol/L) N-HDL (mmol/L)
Normal mice
Control ND - 3.94 ± 0.21 0.71 ± 0.04 5.82 ± 0.34 0.18 ± 0.01 0.11 ± 0.11
SAqFSC-P/ND 1 3.95 ± 0.09 0.67 ± 0.03 6.02 ± 0.28 0.17 ± 0.01 0.23 ± 0.13
9 4.00 ± 0.11 0.63 ± 0.04 6.47 ± 0.30 0.16 ± 0.01 0.25 ± 0.09
PAqFSC-P/ND 1 4.00 ± 0.15 0.63 ± 0.03 6.20 ± 0.36 0.16 ± 0.01 0.23 ± 0.06
9 4.18 ± 0.17 0.63 ± 0.03 6.46 ± 0.29 0.16 ± 0.01 0.17 ± 0.06
Bicyclol/ND 0.025 4.17 ± 0.16 0.70 ± 0.04 6.21 ± 0.48 0.17 ± 0.02 0.10 ± 0.07
Hypercholester-olemic mice
Control ND - 3.10 ± 0.12 0.20 ± 0.02 16.65 ± 1.30 0.06 ± 0.01 0.64 ± 0.03
Control HCBD - 3.02 ± 0.12 1.08 ± 0.07a 2.86 ± 0.17a 0.36 ± 0.02a 2.54 ± 0.14a
SAqFSC-P/HCBD 1 3.15 ± 0.15 1.08 ± 0.06 3.29 ± 0.16 0.31 ± 0.02 2.17 ± 0.12
3 3.20 ± 0.12 1.22 ± 0.09 2.90 ± 0.14 0.35 ± 0.02 2.51 ± 0.19
PAqFSC-P/HCBD 1 3.16 ± 0.10 1.09 ± 0.06 2.72 ± 0.17 0.37 ± 0.02 2.18 ± 0.10b
3 3.08 ± 0.10 0.93 ± 0.05 3.30 ± 0.21 0.35 ± 0.02 1.98 ± 0.11b
Bicyclol/HCBD 0.025 3.27 ± 0.14 1.02 ± 0.07 3.41 ± 0.23 0.31 ± 0.02 2.28 ± 0.13
Experimental details were described in Figure 1. Mice were fed with ND or HCBD containing SAqFSC-P, PAqFSC-P, or bicyclol at the indicated concentration
for 10 days. Serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), HDL/LDL, LDL/HDL, and N-HDL levels were then measured. Mouse model of
hypercholesterolemia was generated by HCBD. Values given are the means ± S.E.M., with n = 10. aP < 0.01 vs. control ND; bP < 0.05 vs. control HCBD, using a
one-way ANOVA follow by Dunnett’s multiple comparisons test or post-hoc analysis.
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markedly increased hepatic TG and TC contents (by 196
and 339%, respectively), when compared with those of
mice fed with ND. Supplementation with SAqFSC-P
and PAqFSC-P at 1% or 3% decreased hepatic TC and
TG contents (by 27 − 46% and 40 − 42%, respectively)
in HCBD-fed mice. However, 3% PAqFSC-P did not
decrease hepatic TC in hypercholesterolemic mice. While
0.025% bicyclol supplementation reduced hepatic TG
content (by 32%) in ND-fed mice, it did not affect hepatic
TG and TC contents in HCBD-fed mice.
Serum and hepatic glucose levels
While supplementation with SAqFSC-P or PAqFSC-P at
a dose of 1% and 9% did not affect the serum GLU levels
in ND- and HCBD-fed mice, HCBD feeding signifi-
cantly decreased serum GLU level by 11% (Figure 3A).
SAqFSC-P or PAqFSC-P supplementation at doses of
1% and 9% decreased hepatic GLU level (by 16 − 31%)
in ND-fed mice. HCBD feeding increased hepatic GLU
level by 19%, when compared with that of mice fed
with ND. Supplementation with SAqFSC-P or PAqFSC-P
at 1% and 3% decreased hepatic GLU level (by 12 − 18%)
in HCBD-fed mice (Figure 3B). While bicyclol supple-
mentation produced no detectable changes in serum
GLU levels in both ND- and HCBD-fed mice, it decreased
hepatic GLU level (by 32%) in ND-fed but not HCBD-
fed mice.Hepatic index/protein/function
Supplementation with PAqFSC-P at 9% increased hepatic
index by 9% in ND-fed mice, but not in HCBD-fed
mice. PAqFSC-P supplementation at 1 or 9% increased
hepatic protein content by 6 and 12% in ND-fed mice,
respectively. However, only 1% SAqFSC-P supplementation
decreased hepatic protein level by 7% in hypercholesterol-
emic mice, when compared with the un-supplemented
HCBD-fed mice. Bicyclol treatment increased hepatic
protein by 11% in ND-fed mice. SAqFSC-P and bicyclol
supplementation suppressed serum ALT activity by 24 and
29%, respectively, in ND-fed mice. Bicyclol also inhibited
ALT activity by 42% in HCBD-fed mice. HCBD feeding
increased hepatic weight, hepatic protein content, and
ALT activity (by 12, 13 and 38%, respectively) (Table 2).
Fatty index
Supplementation with SAqFSC-P at 1% and 9% or PAq
FSC-P at 1% decreased the fatty index (by 15 and 18% or
16%, respectively) in ND-fed mice. HCBD feeding did not
cause any detectable change in fatty index in mice, and
both SAqFSC-P and PAqFSC-P supplementation did not
produce any changes in fatty index in HCBD-fed mice,
except for 1% PAqFSC-P supplementation which caused
a slight but significant decrease (by 13%) in fatty index.
While bicyclol supplementation at 0.025% reduced the
fatty index (by 19%) in ND-fed mice, it did not cause











































































Figure 2 Effects of dietary supplementation with SAqFSC-P,
PAqFSC-P, or bicyclol on hepatic TG and TC contents in normal
and hypercholesterolemic mice. Mice were fed with ND or HCBD
without and with supplementation with SAqFSC-P, PAqFSC-P, or BL
at the indicated concentration for 10 days. Experimental details were
described in Figure 1. Hepatic TG (Figure A) and TC (Figure B) levels
were measured. Value given are the means ± S.E.M., with
n = 10. **P < 0.01 vs. control ND; †P < 0.05, ††P < 0.01 vs. control
HCBD, using a one-way ANOVA followed by Dunnett’s multiple






















































Figure 3 Effects of dietary supplementation with SAqFSC-P,
PAqFSC-P, or bicyclol on serum and hepatic GLU contents in
normal and hypercholesterolemic mice. Mice were fed with ND or
HCBD without and with supplementation with SAqFSC-P or PAqFSC-P,
or BL at the indicated concentration for 10 days. Experimental details
were described in Figure 1. Serum (Figure A) and hepatic (Figure B)
glucose (GLU) levels were measured. Value given are the means ± S.E.
M., with n = 10. **P < 0.01 vs. control ND; ††P < 0.01 vs. control HCBD,
using a one-way ANOVA followed by Dunnett’s multiple comparisons
test or post-hoc analysis.
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Supplementation with SAqFSC-P at 1% or 9% decreased
the body weight gain during the period from D5 to D10
(by 23% and 21%, respectively) in ND-fed mice. Mice fed
with HCBD showed a significant decrease in body weight
gain from D1 to D5 (by 6%). The daily intake of SAqFSC-
P or PAqFSC-P was estimated to be 1.4 − 1.5 g/kg (based
on an equivalent amount of crude herb) at 1% supplemen-
tation, 4.5 − 4.7 g/kg at 3% supplementation in HCBD-fed
mice and 13.6 − 14.2 g/kg/day at 9% supplementation
in ND-fed mice. Bicyclol supplementation decreased
the body weight gain from D5 to D10 (by 17%) in ND-fed
but not HCBD-fed mice. The daily intake of bicyclol
was estimated to be 0.04 g/kg (Table 3). SAqFSC-P andbicyclol supplementation did not reduce the body weight
gain from D1 to D10.
Discussion
Hypercholesterolemia, which is a sub-type of hyperlipid-
emia characterized by significant elevation of serum TC
level, is causally related to the pathogenesis of CHD,
NAFLD, atherosclerosis, diabetes and metabolic syndrome
[20,21]. Unhealthy eating habit is one major cause of
hypercholesterolemia in humans. In this study, except
for serum TG level, both serum and hepatic lipid levels
were found to be increased by feeding HCBD in mice.
Unlike other atherogenic diet containing cholesterol, su-
crose, hydrogenated vegetable oil, sodium cholate, lactose,
Table 2 Effects of dietary supplementation with SAqFSC-P, PAqFSC-P, or bicyclol on hepatic index, protein and func-
tion in normal and hypercholesterolemic mice
Groups Drug concentration (%, w/w) Hepatic index (%) Hepatic protein (g/g liver tissue) Serum ALT activity (U/L)
Normal mice
Control ND - 6.59 ± 0.10 0.138 ± 0.003 36.50 ± 3.61
SAqFSC-P/ND 1 6.76 ± 0.13 0.131 ± 0.003 27.60 ± 0.72a
9 6.91 ± 0.13 0.140 ± 0.004 30.33 ± 2.41
PAqFSC-P/ND 1 6.73 ± 0.11 0.146 ± 0.002a 32.80 ± 1.63
9 7.16 ± 0.17b 0.155 ± 0.003b 32.00 ± 1.81
Bicyclol/ND 0.025 6.69 ± 0.11 0.153 ± 0.002b 26.00 ± 1.67a
Hypercholesterolemic mice
Control ND - 6.43 ± 0.77 0.133 ± 0.004 36.18 ± 2.17
Control HCBD - 7.19 ± 0.13b 0.150 ± 0.002a 50.09 ± 5.81a
SAqFSC-P/HCBD 1 7.17 ± 0.11 0.140 ± 0.005c 47.26 ± 3.58
3 7.06 ± 0.16 0.153 ± 0.003 46.32 ± 2.52
PAqFSC-P/HCBD 1 6.99 ± 0.16 0.147 ± 0.004 47.31 ± 3.38
3 7.04 ± 0.13 0.156 ± 0.003 43.60 ± 3.90
Bicyclol/HCBD 0.025 7.25 ± 0.06 0.149 ± 0.003 29.30 ± 1.52c
Experimental details were described in Figure 1 and Table 1. Mice were fed with ND or HCBD containing SAqFSC-P, PAqFSC-P, or bicyclol at the indicated
concentration for 10 days. Hepatic index (liver weight/body weight × 100), protein (use Bradford assay) and function indicated by alanine aminotransferase (ALT)
were then measured. Mouse model of hypercholesterolemia was generated by HCBD. Values given are the means ± S.E.M., with n = 10. aP < 0.05, bP < 0.01 vs.
control ND; cP < 0.05 vs. control HCBD, using a one-way ANOVA follow by Dunnett’s multiple comparisons test or post-hoc analysis.
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TG and TC levels, HCBD used in this study did not
increase serum TG levels. FSC-P (ie. SAqFSC-P and
PAqFSC-P) intake for 10 days markedly reduced hepatic

















Figure 4 Effects of dietary supplementation with SAqFSC-P,
PAqFSC-P, or bicyclol on fatty index in normal and hypercholes-
terolemic mice. Mice were fed with ND or HCBD without and with
supplementation with SAqFSC-P, PAqFSC-P, or BL at the indicated
concentration for 10 days. Experimental details were described in
Figure 1. Fatty index was estimated from the ratio of epididymal fat
weight to body weight (epididymal fat weight/body weight × 100).
Value given are the means ± S.E.M., with n = 10. *P < 0.05, **P < 0.01 vs.
control ND; †P < 0.05 vs. control HCBD, using a one-way ANOVA
followed by Dunnett’s multiple comparisons test or post-hoc analysis.normal and hypercholesterolemic mice, as compared with
the respective control mice, but it produced no significant
effect on serum TC level. This observation suggested that
the lipid-lowering effect of FSC-P may depend on basal
lipid levels in the body. Our previous study has shown that
schisandrin B, a major active ingredient presented in pulp
fraction of FSC, lowered fat accumulation in L-02 cells
incubated with free fat acid via inhibition of ADRP and
SREBP-1 expression [23]. This might also explain the
hepatic lipid-lowering effects of SAqFSC-P and PAqFSC-P
supplementation. It has been demonstrated that FSC
pulp mainly contains polysaccharides/sugars and organic
acids, as well as dibenzocyclooctadiene lignans such as
schisandrins (A, B, and C) and gomisins (A and N), which
are believed to be the active ingredients in FSC [24,25].
In addition, several other dibenzocyclooctadiene lignans
(Schisandra red pigment) have been isolated from the
fruits of Schisandra wilsoniana [26,27].
LDL in the blood is originated from very low density-
LDL (VLDL) produced in the liver in association with
apoprotein B-100. Being associated with an increased
risk of atherosclerosis and CHD, LDL is also called “bad
cholesterol” [28,29]. In contrast, HDL, which is protective
in nature, is called “good cholesterol”. Hypercholesterol-
emia, including familial hypercholesterolemia, in human
typically shows high levels of LDL and lower levels of
HDL. In the current study, although the serum HDL level
was not reduced, the LDL level was markedly elevated in
hypercholesterolemic mice. Furthermore, LDL/HDL and
Table 3 Effects of dietary supplementation with SAqFSC-P, PAqFSC-P, or bicyclol on body weight gain and food/drug
intake in normal and hypercholesterolemic mice
Groups Drug concentration
(%, w/w)
Body weight gain (g) Food intake
(g/kg/day)
Drug intake
(g/kg/day)D 1→D 5 D 5→D 10
Normal mice
Control ND - 7.41 ± 0.29 4.46 ± 0.22 156.4 -
SAqFSC-P/ND 1 7.52 ± 0.07 3.41 ± 0.18a 142.2 1.42
9 7.19 ± 0.16 3.53 ± 0.27a 157.5 14.18
PAqFSC-P/ND 1 7.42 ± 0.17 3.99 ± 0.36 143.7 1.44
9 7.49 ± 0.35 4.54 ± 0.26 151.4 13.63
Bicyclol/ND 0.025 7.41 ± 0.20 3.70 ± 0.26a 158.3 0.04
Hypercholesterolemic mice
Control ND - 10.42 ± 0.25 3.04 ± 0.14 162.7 -
Control HCBD - 9.76 ± 0.16a 2.81 ± 0.12 151.0 -
SAqFSC-P/HCBD 1 9.71 ± 0.29 3.02 ± 0.10 151.4 1.51
3 9.36 ± 0.20 2.98 ± 0.19 150.0 4.50
PAqFSC-P/HCBD 1 10.02 ± 0.28 2.78 ± 0.11 150.5 1.51
3 9.66 ± 0.15 3.11 ± 0.16 157.5 4.72
Bicyclol/HCBD 0.025 10.36 ± 0.23 2.72 ± 0.13 152.5 0.04
Experimental details were described in Figure 1. The dosages (g/kg/day, based on crude herbal material) were determined with respect to the amount of ingested
diet (g/day/kg) and drug concentration in the diet. Values given are the means ± S.E.M., with n = 10. aP < 0.05 vs. control ND, using a one-way ANOVA followed by
Dunnett’s multiple comparisons test or post-hoc analysis.
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were decreased in mice fed with HCBD-fed mice. As
the predictive indicator of atherosclerosis and coronary
artery calcium [30], high level of LDL and N-HDL caused
by HCBD may hasten the development of hypercholester-
olemia. In addition, the accumulation of fat in hepatic
tissue may lead to liver damage in HCBD-fed mice, as
indicated by an increase in serum ALT activity. FSC-P
did not affect serum HDL and LDL levels in both normal
and hypercholesterolemic mice, but PAqFSC-P decreased
N-HDL values in HCBD-fed mice. N-HDL cholesterol
can predict the risk of CHD [31] and serves as a readily
available parameter for estimating the risk of cognitive
impairment in type 2 diabetic [32]. In this regard, PAqFSC-
P may be used for the prevention of hypercholesterol-
emia related CHD and memory disorders in patients
with diabetes mellitus.
It has been well-known that lipid/fat metabolism has a
close relationship with GLU metabolism. The relevant
metabolic disorders constitute the pathological basis of
modern epidemics such as hyperlipidemia, hyperglycemia,
and hypertension, as well as metabolic syndrome, including
obesity. In this study, HCBD-feeding was found to elevate
serum TC and hepatic TC, TG, and GLU, as well as reduce
serum GLU in mice. As such, the GLU metabolism is
altered by hypercholesterolemic conditions. Studies have
demonstrated that insulin resistance is the pathophysio-
logical hallmark of NAFLD [33,34]. The suppression of
insulin sensitivity results in the accumulation of GLU/fat in the liver, and then leading to the development of
NAFLD. As for HCBD-induced hypoglycemia may be an
event secondary to the elevation in hepatic GLU contents.
It is possible that release of hepatic GLU is inhibited in
the HCBD-fed mice. Low hepatic GLU and lipid levels
caused by FSC-P supplementation might result from
the FSC-P-induced increase in hepatic insulin sensitivity in
HCBD-fed mice [35,36]. FSC-P supplementation decreased
the epididymal fat mass in mice fed with ND. However, due
to the lowered fat index in HCBD-fed mice, FSC-P-induced
fat loss was not observed in hypercholesterolemic mice. On
the other hand, body weight loss was observed during D5
and D10 in ND-fed mice supplemented with SAqFSC-P/
ND. The mechanism underlying the FSC-P-induced loss in
body weight/fat and hepatic lipid may also involve the
inhibition of ADRP and SREBP-1 expression [23].
Previous studies have demonstrated that FSC related
active compounds such as bicyclol, bifendate, and schi-
sandrin B, when administered at high doses, can elevate
serum TG level and hepatic weight in mice. As such, we
have established new animal models of hyperlipidemia
using schisandrin B [37-39] and bifendate [40]. However,
FSC-P extracts used in the present study only produced
minimal effect on serum TG level and hepatic weight.
FSC-P at a high dose (9%, up to 14 g/kg/day for 10 days)
did not affect animal behaviors (data not shown), which
indicated the safety of FSC-P intake on central nervous
system. In addition, serum creatinine levels, indicative of
renal function, were not changed after FSC-P consumption
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dose–response relationship in certain pharmacological
activities of FSC-P, it was evident that FSC-P could signifi-
cantly influence the hepatic lipid profile in hypercholester-
olemic mice. Owing to the fact that chemical components
in an herbal extract produce a wide spectrum of biological
actions, the possible interactions among them may
preclude the display of a dose-dependent relationship
of a pharmacological activity. In the present study, some
effects produced by SAqFSC-P or PAqFSC-P at high dose
(3% or 9%) were less significant than at low dose (1%).
Therefore, caution has to be exercised in determining the
dosage of FSC administration in clinical situations.Table 4 A summary of the current study
















Body weight gain ↓
Hypercholesterolemic mice (change vs. normal)
Serum TC (↑) − ↓
TG (−) ↓ −
HDL (−) − −
LDL (↑) − −
N-HDL (↑) − −
Glucose (↓) − −
ALT activity (↑) − −
Hepatic TC (↑) ↓ ↓
TG (↑) ↓ ↓
Glucose (↑) ↓ ↓
Protein (↑) ↓ −
Index (↑) − −
Fat index (−) − −
Body weight gain (↓) − −
TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density
↑: increased or elevated; ↓: decreased or inhibited; −: unaltered.Despite the fact that biochemical mechanisms under-
lying the development of hyperlipidemia and its compli-
cations are widely investigated, hyperlipidemia remains
the major cause of morbidity and mortality throughout the
world. While the clinical management of hyperlipidemia
has yet to be optimized, Chinese herbs, which have been
used for thousands of years, may serve as an alternative
treatment for hyperlipidemia. In the present study, the
effect of FSC-P was investigated in the mouse model
of hypercholesterolemia. Although both SAqFSC-P and
PAqFSC-P supplementations notably lowered hepatic
TG and GLU contents and elevated hepatic TC levels
in ND-fed mice, no detectable changes were observedupplement Dietary PAqFSC-P supplement Bicyclol
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suggests that the lipid-modulating effect of FSC-P may
be influenced by factors such as lipid levels in tissues.
However, it is still not clear whether dietary FSC-P-
induced increase in hepatic TC content is good or bad
in ND-fed mice. Both SAqFSC-P and PAqFSC-P sup-
plementations decreased serum TG levels and hepatic
TC/TG contents in HCBD-fed mice, but no detectable
effect on serum TC level was observed.
In conclusion, FSC pulp (i.e. SAqFSC-P or PAqFSC-P)
supplementation ameliorated the fatty liver condition in
HCBD-fed mice. FSC pulp supplementation decreased
hepatic GLU and serum TG levels in both ND- and
HCBD-fed mice. However, the supplementation with
bicyclol did not affect serum and hepatic lipid levels in
HCBD-fed mice (summarized in Table 4). SAqFSC-P and
PAqFSC-P produce the similar beneficial outcomes in
hypercholesterolemic mice. Naturally-occurring ingredients
from FSC pulp may provide a safe alternative for the man-
agement of fatty liver and/or lipid disorders in humans.
Materials and methods
Herbal material and extraction procedure
FSC, the fruit of Schisandra Chinensis (Turcz.) Baill.,
was purchased from the Anguo Chinese herbs market
and authenticated by professor Chun-Sheng Liu in the
Beijing University of Chinese Medicine. The fruit pulp
and seed were manually separated, then dried at room
temperature. The weight of pulp and seed was 63% and
37% of total weight, respectively. FSC pulp (300 g) were
powdered and soaked in 300 mL distilled water for 4 h
at room temperature (approximately 25°C), and they
were then washed five times with 300 mL distilled
water. The pooled aqueous extract was centrifuged atFSC-P
FSC-Ps were powdered and 
soaked in distilled water
Figure 5 Preparation of SAqFSC-P and PAqFSC-P. FSC-P: Fructus Schisan
FSC-P; PAqFSC-P: precipitate of aqueous extract of FSC-P.2000 × g for 3 min. The supernatant was concentrated
under reduced pressure by rota-evaporation at 50°C to
obtain 200 mL of SAqFSC-P (i.e., 0.95 g (dry weight) of
FSC-P equivalent for every 1 mL of SAqFSC-P. As for
the sediment, every g (wet weight) of PAqFSC-P was
equivalent to 2.3 g of dried FSC-P. Both SAqFSC-P and
PAqFSC-P were stored at 4°C until use (Figure 5).
Chemicals and reagents
Cholesterol (certificate no. 041103) and bile salt (certifi-
cate no. 000710) were obtained from Beijing Chemical
Reagent Co. (Beijing, China). Fenofibrate (certificate no.
0405030) was bought from Beijing Yongkang Medical Ltd.
(Beijing, China). Bicyclol was purchased from Beijing
Union Pharm. (Beijing, China). Assay kits for TC (certifi-
cate no. 121471), TG (certificate no. 135991) and GLU
(certificate no. 122991) were bought from Zhongsheng
Beikong Bio-technology and Science Inc. (Beijing, China).
Assay kits for HDL and LDL levels, as well as alanine
aminotransferase (ALT) were obtained from Zhongsheng
Beikong Bio-technology and Science Inc. (Beijing, China)
or Beijing Leadman Biochemistry Co., Ltd. (Beijing,
China). Coomassie brilliant blue G250 (certificate no.
20130624) was purchased from Nanjing Jiancheng Bio-
engineering Institute (Nanjing, China).
Animal treatment
Male ICR mice [Grade II, certificate No. SCXK (jing)
2006–0009], weighing 17–20 g (two-month-old), and the
standard mouse chow diet were supplied by Vital River
Lab Animal Co. Ltd. (Beijing, China). All animals were
maintained on a 12 h (light on 700–1900 h) light–dark
cycle at 20–21°C, with a relative humidity of 50 − 55%.
They were allowed free access to water and food. BloodSAqFSC-P
PAqFSC-P
drae Chinensis pulp; SAqFSC-P: supernatant of aqueous extract of
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anesthetized animals which had been fasted for 6 h
(from 600 to 1200). All experimental procedures were
approved by the University Committee on Research
Practice in Beijing University of Chinese Medicine.
Study design 1: normal diet (ND)-fed mice
This study was aimed to examine whether the oral ad-
ministration of FSC-P could produce any toxic effects in
mice fed with ND. Mice were divided into 6 groups of
10 animals in each: (1) control mice fed with ND; (2)
and (3) mice fed with ND supplemented with 1% and
9% (w/w) SAqFSC-P, respectively; (4) and (5) mice fed
with ND supplemented with 1% and 9% PAqFSC-P,
respectively; and (6) mice fed ND supplemented with
0.025% bicyclol. Currently, bicyclol (a synthetic derivative
of dibenzocyclooctadiene lignan from FSC) is used to treat
hepatitis in China. Therefore, bicyclol was selected as a
positive control. Mice were sacrificed ten days after the
drug treatment.
Study design 2: High cholesterol/bile salt diet
(HCBD)-fed mice
This study was aimed to investigate whether the oral
administration of FSC-P could produce any beneficial
effect on mice fed with HCBD containing cholesterol/
bile salt (1%/0.3%, w/w). Seventy mice were randomly
assigned to seven groups of 10 animals in each: (1) control
mice fed with ND; (2) control (ie. untreated) mice fed with
HCBD; (3)-(6) mice fed with HCBD supplemented with
SAqFSC-P or PAqFSC-P at 1% and 3% (w/w); (7) mice fed
with HCBD supplemented with bicyclol at 0.025%. Ten
days later mice were killed and biochemical analyses were
performed. Our previous studies showed that high levels
of serum and hepatic lipids were observed in mice after
10 days on high-fat diet [15-19].
Biochemical analysis
Serum and liver samples were obtained 24 h after the last
day of the experiment. Serum samples were prepared by
centrifuging the whole blood obtained from the orbital
vein for 8 min at 2000 × g and stored at −70°C until
use for biochemical analyses. Liver tissue samples were
homogenized in 9 volumes of saline solution by two
10-s bursts of a tissue disintegrator at 13,500 rpm. The
homogenates were then centrifuged at 2000 × g for 15 min
to obtain the supernatants. Thirty μL of the hepatic
supernatant and 10 μL serum was used to determine
TG and TC levels with GPO-PAP and COD-PAP
method, respectively. Ten μL serum and 5 μL hepatic
supernatant were used to determine the GLU levels
with GOD-POD method. One hundred μL of hepatic
supernatant were used to measure protein level using
Bradford assay. Assays were performed by using assaykits according to the manufacturer’s instructions. HDL/
LDL, LDL/HDL and N-HDL values were estimated by
calculating the ratio of HDL to LDL and LDL to HDL,
and the difference between TC and HDL, respectively.
ALT activity was measured by automatic Biochemistry
Analyzer (Beckman coulter Synchron CX4 PRO, Brea,
CA, USA).
Measurement of hepatic index and fatty index
Liver weight was measured and hepatic index was estimated
from the ratio of liver weight to body weight (liver weight/
body weight × 100). Epididymal fat weight was measured
and fatty index was estimated from the ratio of fat weight
to body weight (epididymal fat weight/body weight × 100).
Statistical analysis
Data were expressed as means ± S.E.M., and they were
analyzed by One-way ANOVA followed by Dunnett’s
multiple comparison test or post-hoc analysis using
SPSS 16.0 statistical analysis program. P < 0.05 was
considered as significant.
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